All Pharma News
Immutep: Positive IO Combo Data In Soft Tissue Sarcoma Phase 2

Immutep: Positive IO Combo Data In Soft Tissue Sarcoma Phase 2
GLOBENEWSWIRE
02 May 2024
Share Share
Immutep Quarterly Activities Report Q3 FY24

Immutep Quarterly Activities Report Q3 FY24
GLOBENEWSWIRE
29 Apr 2024
Share Share
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
GLOBENEWSWIRE
24 Apr 2024
Share Share
Immutep Taps Institute For First-In-Human Phase 1 Study Of IMP761

Immutep Taps Institute For First-In-Human Phase 1 Study Of IMP761
GLOBENEWSWIRE
18 Apr 2024
Share Share
Immutep Receives Positive Feedback for TACTI-004 Lung Cancer Trial

Immutep Receives Positive Feedback for TACTI-004 Lung Cancer Trial
GLOBENEWSWIRE
17 Apr 2024
Share Share
Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Announces First Clinical Data from 90mg Dosing of Efti
GLOBENEWSWIRE
05 Mar 2024
Share Share
Immutep Quarterly Activities Report Q2 FY24

Immutep Quarterly Activities Report Q2 FY24
GLOBENEWSWIRE
30 Jan 2024
Share Share
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Trial

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Trial
GLOBENEWSWIRE
21 Dec 2023
Share Share
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
GLOBENEWSWIRE
22 Nov 2023
Share Share
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA
GLOBENEWSWIRE
09 Nov 2023
Share Share